Publication showing Ivermectin of no use treating COVID
Another science-based report that the use of ivermectin is not indicated in treating mild to moderate covid infections. When will the non-scientists start believing in science?
IMPORTANCE The effectiveness of ivermectin to shorten symptom duration or prevent
hospitalization among outpatients in the US with mild to moderate symptomatic
COVID-19 is unknown.
OBJECTIVE To evaluate the efficacy of ivermectin, 400 μg/kg, daily for 3 days compared with
placebo for the treatment of early mild to moderate COVID-19.
DESIGN, SETTING, AND PARTICIPANTS ACTIV-6, an ongoing, decentralized, double-blind,
randomized, placebo-controlled platform trial, was designed to evaluate repurposed
therapies in outpatients with mild to moderate COVID-19. A total of 1591 participants aged 30
years and older with confirmed COVID-19, experiencing 2 or more symptoms of acute
infection for 7 days or less, were enrolled from June 23, 2021, through February 4, 2022,
with follow-up data through May 31, 2022, at 93 sites in the US.
INTERVENTIONS Participants were randomized to receive ivermectin, 400 μg/kg (n = 817),
daily for 3 days or placebo (n = 774).
MAIN OUTCOMES AND MEASURES Time to sustained recovery, defined as at least 3
consecutive days without symptoms. There were 7 secondary outcomes, including
a composite of hospitalization or death by day 28.
RESULTS Among 1800 participants who were randomized (mean [SD] age, 48 [12] years; 932
women [58.6%]; 753 [47.3%] reported receiving at least 2 doses of a SARS-CoV-2 vaccine),
1591 completed the trial. The hazard ratio (HR) for improvement in time to recovery was 1.07
(95%credible interval [CrI], 0.96-1.17; posterior P value [HR >1] = .91). The median time to
recovery was 12 days (IQR, 11-13) in the ivermectin group and 13 days (IQR, 12-14) in the
placebo group. There were 10 hospitalizations or deaths in the ivermectin group and 9 in the
placebo group (1.2%vs 1.2%; HR, 1.1 [95%CrI, 0.4-2.6]). The most common serious adverse
events were COVID-19 pneumonia (ivermectin [n = 5]; placebo [n = 7]) and venous
thromboembolism (ivermectin [n = 1]; placebo [n = 5]).
CONCLUSIONS AND RELEVANCE Among outpatients with mild to moderate COVID-19,
treatment with ivermectin, compared with placebo, did not significantly improve time to
recovery. These findings do not support the use of ivermectin in patients with mild
to moderate COVID-19.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT04885530
IMPORTANCE The effectiveness of ivermectin to shorten symptom duration or prevent
hospitalization among outpatients in the US with mild to moderate symptomatic
COVID-19 is unknown.
OBJECTIVE To evaluate the efficacy of ivermectin, 400 μg/kg, daily for 3 days compared with
placebo for the treatment of early mild to moderate COVID-19.
DESIGN, SETTING, AND PARTICIPANTS ACTIV-6, an ongoing, decentralized, double-blind,
randomized, placebo-controlled platform trial, was designed to evaluate repurposed
therapies in outpatients with mild to moderate COVID-19. A total of 1591 participants aged 30
years and older with confirmed COVID-19, experiencing 2 or more symptoms of acute
infection for 7 days or less, were enrolled from June 23, 2021, through February 4, 2022,
with follow-up data through May 31, 2022, at 93 sites in the US.
INTERVENTIONS Participants were randomized to receive ivermectin, 400 μg/kg (n = 817),
daily for 3 days or placebo (n = 774).
MAIN OUTCOMES AND MEASURES Time to sustained recovery, defined as at least 3
consecutive days without symptoms. There were 7 secondary outcomes, including
a composite of hospitalization or death by day 28.
RESULTS Among 1800 participants who were randomized (mean [SD] age, 48 [12] years; 932
women [58.6%]; 753 [47.3%] reported receiving at least 2 doses of a SARS-CoV-2 vaccine),
1591 completed the trial. The hazard ratio (HR) for improvement in time to recovery was 1.07
(95%credible interval [CrI], 0.96-1.17; posterior P value [HR >1] = .91). The median time to
recovery was 12 days (IQR, 11-13) in the ivermectin group and 13 days (IQR, 12-14) in the
placebo group. There were 10 hospitalizations or deaths in the ivermectin group and 9 in the
placebo group (1.2%vs 1.2%; HR, 1.1 [95%CrI, 0.4-2.6]). The most common serious adverse
events were COVID-19 pneumonia (ivermectin [n = 5]; placebo [n = 7]) and venous
thromboembolism (ivermectin [n = 1]; placebo [n = 5]).
CONCLUSIONS AND RELEVANCE Among outpatients with mild to moderate COVID-19,
treatment with ivermectin, compared with placebo, did not significantly improve time to
recovery. These findings do not support the use of ivermectin in patients with mild
to moderate COVID-19.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT04885530
80-89, M
